Items where Author is "Sabel, Michael"

Article

Zeyen, Thomas and Potthoff, Anna-Laura and Nemeth, Robert and Heiland, Dieter H. and Burger, Michael C. and Steinbach, Joachim P. and Hau, Peter and Tabatabai, Ghazaleh and Glas, Martin and Schlegel, Uwe and Grauer, Oliver and Krex, Dietmar and Schnell, Oliver and Goldbrunner, Roland and Sabel, Michael and Thon, Niklas and Delev, Daniel and Clusmann, Hans and Seidel, Clemens and Gueresir, Erdem and Schmid, Matthias and Schuss, Patrick and Giordano, Frank A. and Radbruch, Alexander and Becker, Albert and Weller, Johannes and Schaub, Christina and Vatter, Hartmut and Schilling, Judith and Winkler, Frank and Herrlinger, Ulrich and Schneider, Matthias (2022) Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial. TRIALS, 23 (1): 57. ISSN , 1745-6215

Weller, Johannes and Schaefer, Niklas and Schaub, Christina and Potthoff, Anna-Laura and Steinbach, Joachim P. and Schlegel, Uwe and Sabel, Michael and Hau, Peter and Seidel, Clemens and Krex, Dietmar and Goldbrunner, Roland and Pietsch, Torsten and Tzaridis, Theophilos and Zeyen, Thomas and Borger, Valeri and Guresir, Erdem and Vatter, Hartmut and Herrlinger, Ulrich and Schneider, Matthias (2022) Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS. JOURNAL OF NEURO-ONCOLOGY, 159 (1). pp. 95-101. ISSN 0167-594X, 1573-7373

Tzaridis, Theophilos and Schaefer, Niklas and Weller, Johannes and Steinbach, Joachim-Peter and Schlegel, Uwe and Seidel, Sabine and Sabel, Michael and Hau, Peter and Seidel, Clemens and Krex, Dietmar and Goldbrunner, Roland and Tonn, Joerg-Christian and Grauer, Oliver and Kebir, Sied and Schneider, Matthias and Schaub, Christina and Vatter, Hartmut and Coch, Christoph and Glas, Martin and Fimmers, Rolf and Pietsch, Torsten and Reifenberger, Guido and Herrlinger, Ulrich and Felsberg, Joerg (2021) MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial. INTERNATIONAL JOURNAL OF CANCER, 148 (7). pp. 1695-1707. ISSN 0020-7136, 1097-0215

Kamp, Marcel A. and Malzkorn, Bastian and von Sass, Christiane and DiMeco, Francesco and Hadjipanayis, Constantinos G. and Senft, Christian and Rapp, Marion and Gepfner-Tuma, Irina and Fountas, Konstantinos and Krieg, Sandro M. and Neukirchen, Martin and Florian, Ioan Stefan and Schnell, Oliver and Mijderwijk, Hendrik-Jan and Perin, Alessandro and Baumgarten, Peter and van Lieshout, Jasper H. and Thon, Niklas and Renovanz, Miriam and Kahlert, Ulf and Spoor, Jochem K. H. and Haenggi, Daniel and McLean, Aaron Lawson and Maeurer, Matthias and Sarrubbo, Silvio and Freyschlag, Christian F. and Schmidt, Nils O. and Vergani, Francesco and Jungk, Christine and Stein, Marco and Forster, Marie-Therese and Weinberg, Jeffrey S. and Sinclair, John and Belykh, Evgenii and Bello, Lorenzo and Mandonnet, Emmanuel and Moiyadi, Aliasgar and Sabel, Michael (2021) Proposed definition of competencies for surgical neuro-oncology training. JOURNAL OF NEURO-ONCOLOGY, 153 (1). pp. 121-131. ISSN 0167-594X, 1573-7373

Kebir, Sied and Schaub, Christina and Junold, Nina and Hattingen, Elke and Schaefer, Niklas and Steinbach, Joachim P. and Weyerbrock, Astrid and Hau, Peter and Goldbrunner, Roland and Galldiks, Norbert and Weller, Johannes and Mack, Frederic and Tzaridis, Theophilos and Baehr, Oliver and Seidel, Clemens and Schlegel, Uwe and Schmidt-Graf, Friederike and Rohde, Veit and Borchers, Christian and Tabatabai, Ghazaleh and Haenel, Mathias and Sabel, Michael and Gerlach, Ruediger and Krex, Dietmar and Belka, Claus and Vatter, Hartmut and Proescholdt, Martin and Glas, Martin and Herrlinger, Ulrich (2019) Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. JOURNAL OF NEURO-ONCOLOGY, 144 (3). pp. 501-509. ISSN 0167-594X, 1573-7373

Herrlinger, Ulrich and Tzaridis, Theophilos and Mack, Frederic and Steinbach, Joachim Peter and Schlegel, Uwe and Sabel, Michael and Hau, Peter and Kortmann, Rolf-Dieter and Krex, Dietmar and Grauer, Oliver and Goldbrunner, Roland and Schnell, Oliver and Baehr, Oliver and Uhl, Martin and Seidel, Clemens and Tabatabai, Ghazaleh and Kowalski, Thomas and Ringel, Florian and Schmidt-Graf, Friederike and Suchorska, Bogdana and Brehmer, Stefanie and Weyerbrock, Astrid and Renovanz, Miriam and Bullinger, Lars and Galldiks, Norbert and Vajkoczy, Peter and Misch, Martin and Vatter, Hartmut and Stuplich, Moritz and Schaefer, Niklas and Kebir, Sied and Weller, Johannes and Schaub, Christina and Stummer, Walter and Tonn, Joerg-Christian and Simon, Matthias and Keil, Vera C. and Nelles, Michael and Urbach, Horst and Coenen, Martin and Wick, Wolfgang and Weller, Michael and Fimmers, Rolf and Schmid, Matthias and Hattingen, Elke and Pietsch, Torsten and Coch, Christoph and Glas, Martin (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. LANCET, 393 (10172). pp. 678-688. ISSN 0140-6736, 1474-547X

Schaefer, Niklas and Proescholdt, Martin and Steinbach, Joachim P. and Weyerbrock, Astrid and Hau, Peter and Grauer, Oliver and Goldbrunner, Roland and Friedrich, Franziska and Rohde, veit and Ringel, Florian and Schlegel, Uwe and Sabel, Michael and Ronellenfitsch, Michael W. and Uhl, Martin and Grau, Stefan and Haenel, Mathias and Schnell, Oliver and Krex, Dietmar and Vajkoczy, Peter and Tabatabai, Ghazaleh and Mack, Frederic and Schaub, Christina and Tzaridis, Theophilos and Niessen, Michael and Kebir, Sied and Leutgeb, Barbara and Urbach, Horst and Belka, Claus and Stummer, Walter and Glas, Martin and Herrlinger, Ulrich (2018) Quality of life in the GLARIUS trial randomizing bevacizumab/ irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. NEURO-ONCOLOGY, 20 (7). pp. 975-985. ISSN 1522-8517, 1523-5866

Schaub, Christina and Kebir, Sied and Junold, Nina and Hattingen, Elke and Schaefer, Niklas and Steinbach, Joachim P. and Weyerbrock, Astrid and Hau, Peter and Goldbrunner, Roland and Niessen, Michael and Mack, Frederic and Stuplich, Moritz and Tzaridis, Theophilos and Baehr, Oliver and Kortmann, Rolf-Dieter and Schlegel, Uwe and Schmidt-Graf, Friederike and Rohde, Veit and Braun, Christian and Haenel, Mathias and Sabel, Michael and Gerlach, Ruediger and Krex, Dietmar and Belka, Claus and Vatter, Hartmut and Proescholdt, Martin and Herrlinger, Ulrich and Glas, Martin (2018) Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 144 (8). pp. 1581-1589. ISSN 0171-5216, 1432-1335

Herrlinger, Ulrich and Schaefer, Niklas and Steinbach, Joachim P. and Weyerbrock, Astrid and Hau, Peter and Goldbrunner, Roland and Friedrich, Franziska and Rohde, Veit and Ringel, Florian and Schlegel, Uwe and Sabel, Michael and Ronellenfitsch, Michael W. and Uhl, Martin and Maciaczyk, Jaroslaw and Grau, Stefan and Schnell, Oliver and Haenel, Mathias and Krex, Dietmar and Vajkoczy, Peter and Gerlach, Ruediger and Kortmann, Rolf-Dieter and Mehdorn, Maximilian and Tuettenberg, Jochen and Mayer-Steinacker, Regine and Fietkau, Rainer and Brehmer, Stefanie and Mack, Frederic and Stuplich, Moritz and Kebir, Sied and Kohnen, Ralf and Dunkl, Elmar and Leutgeb, Barbara and Proescholdt, Martin and Pietsch, Torsten and Urbach, Horst and Belka, Claus and Stummer, Walter and Glas, Martin (2016) Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O-6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. JOURNAL OF CLINICAL ONCOLOGY, 34 (14). 1611-U134. ISSN 0732-183X, 1527-7755

Galldiks, Norbert and Dunkl, Veronika and Stoffels, Gabriele and Hutterer, Markus and Rapp, Marion and Sabel, Michael and Reifenberger, Guido and Kebir, Sied and Dorn, Franziska and Blau, Tobias and Herrlinger, Ulrich and Hau, Peter and Ruge, Maximilian I. and Kocher, Martin and Goldbrunner, Roland and Fink, Gereon R. and Drzezga, Alexander and Schmidt, Matthias and Langen, Karl-Josef (2015) Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[F-18]fluoroethyl)-L-tyrosine PET. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 42 (5). pp. 685-695. ISSN 1619-7070, 1619-7089

Suchorska, Bogdana and Weller, Michael and Tabatabai, Ghazaleh and Senft, Christian and Hau, Peter and Sabel, Michael and Herrlinger, Ulrich and Ketter, Ralf and Schlegel, Uwe S. and Marosi, Christine and Reifenberger, Guido and Wick, Wolfgang and Tonn, Joerg and Wirsching, Hans-Georg (2015) Does extent of resection matter in recurrent glioblastoma? Lessons from the DIRECTOR trial. JOURNAL OF CLINICAL ONCOLOGY, 33 (15supp): 2041. ISSN 0732-183X, 1527-7755

Tabatabai, Ghazaleh and Wick, Wolfgang and Reifenberger, Guido and Steinbach, Joachim Peter and Schnell, Oliver and Hau, Peter and Herrlinger, Ulrich and Sabel, Michael and Ketter, Ralf and Schlegel, Uwe S. and Marosi, Christine and Goldbrunner, Roland and Homicsko, Krisztian and Nikkhah, Guido and Pichler, Josef and Vajkoczy, Peter and Meixensberger, Juergen and Weller, Michael (2013) Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma (DIRECTOR). JOURNAL OF CLINICAL ONCOLOGY, 31 (15supp): TPS2103. ISSN 0732-183X, 1527-7755

Conference or Workshop Item

Weller, Johannes and Zeyen, Thomas and Schlegel, Uwe and Lazaridis, Lazaros and Werner, Jan-Michael and Onken, Julia and Zeiner, Pia and Drexler, Richard and Hau, Peter and Seidel, Clemens and Grosse, Lucia and Clusmann, Hans and Sabel, Michael and Ringel, Florian and Pichler, Josef and Grauer, Oliver and Hundsberger, Thomas and Schnell, Oliver and Mair, Maximilian J. and Uhl, Martin and Schmidt-Graf, Friederike and Glas, Martin and Galldiks, Norbert and Unteroberdoerster, Meike and Steinbach, Joachim and Ricklefs, Franz and Renovanz, Mirjam and Delev, Daniel Ivanov and Turgut, Merih O. and Flesch, Oliver R. and Cipriani, Debora and Preusser, Matthias and Kebir, Sied and Misch, Martin and Goldbrunner, Roland and Westphal, Manfred and Tabatabai, Ghazaleh and Schaefer, Niklas and Schneider, Matthias and Vatter, Hartmut and Giordano, Frank and Schaub, Christina and Herrlinger, Ulrich (2022) CTNI-07. LOMUSTINE/TEMOZOLOMIDE CHEMOTHERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED IDHWT GLIOBLASTOMA ACCORDING TO CETEG/NOA-09: REAL-WORLD EXPERIENCE IN A MULTICENTER COHORT. In: 27th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 16-20, 2022, Tampa Bay, FL.

Weller, Johannes and Waha, Andreas and Schneider, Matthias and Seidel, Clemens and Steinbach, Joachim and Hau, Peter and Schlegel, Uwe and Tonn, Joerg-Christian and Grauer, Oliver and Sabel, Michael and Krex, Dietmar and Schnell, Oliver and Ringel, Florian and Tabatabai, Ghazaleh and Goldbrunner, Roland and Radbruch, Alexander and Schuss, Patrick and Gueresir, Erdem and Vatter, Hartmut and Glas, Martin and Schmid, Matthias and Schafer, Niklas and Tzaridis, Theophilos and Giordano, Frank and Zeyen, Thomas and Schaub, Christina and Nemeth, Robert and Pietsch, Torsten and Herrlinger, Ulrich (2021) DNA METHYLATION-BASED SUBGROUPING PREDICTS SURVIVAL BENEFIT FROM LOMUSTINE/TEMOZOLOMID COMBINATION THERAPY IN MGMT PROMOTOR-METHYLATED GLIOBLASTOMA. In: 26th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 18-21, 2021, Boston, MA.

Other

Tzaridis, Theophilos and Schaefer, Niklas and Weller, Johannes and Steinbach, Joachim and Seidel, Sabine and Schlegel, Uwe and Sabel, Michael and Hau, Peter and Seidel, Clemens and Krex, Dietmar and Goldbrunner, Roland and Tonn, Joerg-Christian and Grauer, Oliver and Schaub, Christina and Coch, Christoph and Glas, Martin and Pietsch, Torsten and Fimmers, Rolf and Reifenberger, Guido and Felsberg, Joerg and Herrlinger, Ulrich (2019) MGMT PROMOTER METHYLATION ANALYSIS FOR ALLOCATING COMBINED CCNU/TMZ CHEMOTHERAPY: LESSONS LEARNED FROM THE CeTeG/NOA-09 TRIAL. OXFORD UNIV PRESS INC, CARY.

Herrlinger, Ulrich and Tzaridis, Theophilos and Mack, Frederic and Steinbach, Joachim and Schlegel, Uwe and Sabel, Michael and Hau, Peter and Kortman, Rolf-Dieter and Krex, Dietmar and Grauer, Oliver and Goldbrunner, Roland and Schnell, Oliver and Baehr, Oliver and Uhl, Martin and Tabatabai, Ghazaleh and Ringel, Florian and Schmidt-Graf, Friederike and Brehmer, Stefanie and Weyerbrock, Astrid and Bullinger, Lars and Vajkoczy, Peter and Vatter, Hartmut and Schaefer, Niklas and Kebir, Sied and Weller, Johannes and Stummer, Walter and Simon, Matthias and Keil, Vera and Nelles, Michael and Fimmers, Rolf and Pietsch, Torsten and Hattingen, Elke and Coch, Christoph and Glas, Martin (2017) PHASE III TRIAL OF CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA PATIENTS: THE CeTeg/NOA-09 trial. OXFORD UNIV PRESS INC, CARY.

Wick, Wolfgang and Roth, Patrick and Wiestler, Benedikt and Hartmann, Christian and Hau, Peter and Nakamura, Makoto and Stockhammer, Florian and Sabel, Michael and Koeppen, Susanne and Ketter, Ralf and Vajkoczy, Peter and Eyupoglus, Ilker and Kaendler, Stephen and Kalff, Rolf and Galldiks, Norbert and Schmidt-Graf, Friederike and von Deimling, Andreas and Platten, Michael and Reifenberger, Guido and Weller, Michael (2015) Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. AMER SOC CLINICAL ONCOLOGY, ALEXANDRIA.

Tabatabal, Ghazaleh and Wick, Wolfgang and Steinbach, Joachim Peter and Wick, Antje and Schnell, Oliver and Hau, Peter and Herrlinger, Ulrich and Sabel, Michael and Wlrsching, Hans-Georg and Ketter, Ralf and Baehr, Oliver and Platten, Michael and Tonn, Joerg and Huesing, Johannes and Reifenberger, Guido and Weller, Michael (2014) MGMT promoter methylation as a prognostic biomarker for benefit front dose-intensified temozolomide rechallenge in progressive glioblastoma; First results from the randomized phase II DIRECTOR trial. AMER SOC CLINICAL ONCOLOGY, ALEXANDRIA.